FDA unveils rare disease innovation hub, plans public meeting this fall
Regulatory NewsEmily Hayes
Biologics/ biosimilars/ vaccinesBiotechnologyCBERCDEROrphan drugsPharmaceuticalsProduct developmentProduct LifecycleRegulatory NewsEmily HayesBiologics/ biosimilars/ vaccinesBiotechnologyCBERCDEROrphan drugsPharmaceuticalsProduct developmentProduct Lifecycle